Diana Bartlett

Diana Bartlett serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of scientific and operational capabilities. She manages complex contracting actions focused on research and development in the life sciences, enabling critical public health infrastructure including laboratory diagnostics, infectious disease surveillance systems, and data analytics platforms. Her work directly supports CDC’s rapid response to emerging health threats by ensuring timely access to advanced biomedical technologies and analytical services essential for epidemiological research and laboratory capacity building. Bartlett maintains sustained partnerships with leading contractors including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, Cepheid, and the New York City Health & Hospitals Corp. These relationships are characterized by long-term, mission-critical engagements in diagnostic assay development, clinical trial support, biosafety infrastructure, and real-time data integration systems. Her contracting approach emphasizes technical rigor, performance-based outcomes, and compliance with federal biomedical procurement standards, fostering collaborative vendor partnerships that align with CDC’s scientific and operational priorities. Her procurement activity reflects a strict focus on open competition, with 100% of awards issued under no set-aside categories. This underscores a preference for technical excellence and scale over socioeconomic preferences, prioritizing capability and mission alignment over vendor classification. While small business participation is not formally targeted, all procurements adhere to full and open competition requirements under FAR Part 6, ensuring the selection of the most qualified providers regardless of size or certification. Bartlett’s portfolio is exclusively centered on NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—reflecting deep expertise in procuring advanced biotechnology, molecular diagnostics, genomic sequencing tools, and public health data systems. Her acquisitions support cutting-edge scientific research, laboratory modernization, and the deployment of next-generation infectious disease detection platforms critical to national preparedness.